High res bio business network 2010 brochure

1,847 views
1,772 views

Published on

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,847
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

High res bio business network 2010 brochure

  1. 1. BACK BY POPULAR DEMAND! B o sa an ok ve d ea up Top £2 rly to “ The size and exclusivity 00 of the audience make it an extremely productive bio-partnering event ” Speakers Margaret Beer, Gary Buell, 29th – 30th September 2010 Senior Director and Head of Licensing Head of Search and Intercontinental Hotel, Geneva and External Research, Merck & Co Evaluation, Merck Serono Creating Value-Generating Louk Pechtold, Director Business Partnerships, Strengthening Development, Roche Relationships And Growing Onno van de Stolpe, CEO, Galapagos Pipelines Marianne De Backer, Director Technology Licensing, Johnson & Johnson Peter Luke, Senior Director Strategic Alliances, Pfizer Vincent Mutel, CEO, Addex Pharmaceuticals Roel Bulthuis, Head of Merck Serono Ventures, Merck Serono The Most Productive Conference For Partnering Carlos de Sousa, Vice-President Corporate Meetings And High-Level Networking Licensing, Nycomed I An exclusive, niche forum for decision-makers from biotech and Graziano Seghezzi, pharmaceutical companies Partner, Sofinnova Partners I Over 900 1-2-1 meetings give you and your colleagues the Kees Been, opportunity to initiate deals and develop successful partnerships CEO, Envivo Pharma I First-hand case studies on the latest deals including the Denise Goode, Executive Transaction Roche / Galapagos alliance and the AstraZeneca / Director, Strategic Planning Novexel acquisition and Business Development, AstraZeneca I Over 10 hours of networking built into the programme: Iain Buchanan, make new contacts and build new relationships CEO, Novexel I Be a part of the Biotech Investment Challenge: Lubor Gaal, attract new partners and hear live feedback Director, External Science Technology & Licensing, from our line-up of pharma experts Bristol Myers-Squibb Sponsored By: Supported by: Organised By: +44 (0) 207 368 9465 biobusiness@wbr.co.uk www.biobusinessnetwork.com 6133 AW.indd 2 28/05/2010 16:44
  2. 2. 29th – 30th September 2010, Intercontinental Hotel, Geneva Dear Colleague The Most Productive Conference For As the BioBusiness Network Advisory Board, we are delighted to 1-2-1 Meetings invite you to join us at BioBusiness Network 2010 on 29th and 30th At no event will you have as many productive and meaningful September 2010 in Geneva. 1-2-1 meetings with potential partners. Why? Quite simple. Our This year, we are pleased to bring you an even more focused audience has a unique pharma-biotech split, a complete focus programme that has been designed to give you senior-level on business development and licensing and is almost exclusively networking, high-quality partnering meetings and top level limited to top decision-makers, positioning BioBusiness Network as insight over two value-packed days. the conference of choice for deal-makers. BioBusiness Network 2010 will be your rst opportunity after the summer to catch up on the latest partnering opportunities, hear about market developments and meet the leading Industry decision-makers in the market. This year’s event is rmly I Pharma ..........................................................47% cemented as THE place to make critical contacts and further your I Biotech ..........................................................48% pipelines. With the latest deal-case studies and cutting-edge I Other .................................................................5% market information from leading big pharma and biotechs, you can be sure you’ll leave the event with contacts you need to achieve strategic growth through partnerships. In the conference sessions, you will hear from more senior speakers than ever before including pharma experts from Roche, Seniority Merck Serono, Johnson & Johnson, Bristol Myers Squibb and I C-level ............................................................24% AstraZeneca. Plus, you will learn from the most innovative biotechs I VP......................................................................56% from Novexel, Alligator BioScience, Intercell, Lectus Therapeutics I Director .........................................................14% and more! I Other .................................................................6% This is a unique opportunity to meet, network with and learn from your peers, competitors and partners in an increasingly competitive market. Make sure you register today to: Function • Receive updates first-hand on the biggest and highest- I Business Development pro le deals and Licensing............................................88% • Evaluate your nancing options in a challenging funding I Alliance Management ............................8% environment I Other .................................................................4% • Benefit from one-to-one meetings to capitalise on niche, high- margin opportunities with the industry ’s movers and shakers • Take part in the BioBusiness Investment Challenge and showcase your business amongst the very best I look forward to meeting you in Geneva. “ I attend many conferences in my role at GSK but I certainly found this event to be Best regards of a very high quality and very useful ” Christoph Huels, PhD Kate Burt Member of the Advisory Board for BioBusiness Network 2010 Director Alliances and Transactions, GSK Head of Early Stage Licensing, Merck Serono The BioBusiness Network 2010 Advisory Board Ensuring BioBusiness Network is produced for the industry, by the industry Dr. Christoph Huels Carlos de Sousa Dr Manfred Horst Vice President Early Stage Licensing Vice-President Corporate Licensing Director Scienti c Liaison, France Merck Serono Nycomed and Germany Merck and Co Kees Been Onno van de Stolpe CEO CEO Envivo Pharma Galapagos +44 (0) 207 368 9465 biobusiness@wbr.co.uk www.biobusinessnetwork.com 6133 AW.indd 3 28/05/2010 16:45
  3. 3. 29th – 30th September 2010, Intercontinental Hotel, Geneva Make The Most Out Of Your Two Days At BioBusiness Network The BioBusiness Network 2010 Promise BioBusiness Network isn’t focused on being the biggest bio-partnering event. (After all, how many people can you realistically meet over two days?) What we do guarantee you is high-quality networking and face-to-face time with all the people you want to meet. We deliberately cap the number of attendees at BioBusiness Network to ensure the event remains intimate and e ective for networking. No one wants to spend their days ghting through crowds of irrelevant people and BioBusiness Network cuts them out to help you ensure all your conversations have a focused business goal in mind. One-To-One Partnering Meetings Unrivalled Networking Our cutting-edge partnering software guarantees you make full use of your We know you come to the event rst and foremost to connect with your peers time on site. You can: so we have done everything possible to enhance the networking experience. • Upload a personalised company profile giving you immediate stand-out BioBusiness Network 2010 brings you even more e ective networking. Our • Identify the precise partnering opportunities that meet your corporate attendees come back year after year because they know they’ll have more objectives opportunities to have quality face-to-face time with senior-level partners than anywhere else. • Browse all attendee pro les to select your meeting partners based on your business needs With structured networking throughout the programme as well as time for more informal networking, we give you every opportunity to spend time • Get up-to-date information about your partners’ current projects and with the people you want to meet. opportunities • Line-up your meetings ahead of the conference In-Depth Conference Programme Take The Investment Challenge The BioBusiness Network conference programme features the most senior We’re now taking applications for the Investment Challenge – where biotechs speaker line-up in Europe. Where else could you hear from (and meet with) are o ered the opportunity to pitch big pharma investors live on stage – decision-makers from top 10 pharma as well as the leading biotech companies? and to get open and honest feedback on their performance. Gain invaluable We control the content of the BioBusiness agenda to ensure it add maximum insight into what sparks the interest of potential partners and investors. value to your time at the conference. With high-level panel discussions, case For the rst time, the Investment Challenge presents categories in six key studies and insights, you’ll have to plan your networking carefully to take it all therapeutic areas. in! To apply for a place, email biobusiness@wbr.co.uk with a 250-word company BioBusiness Network 2010: where the future of bio-partnering overview. Successful candidates will be informed by 31st August 2010. in shaped Take A Company Pro le And Promote Your Brand Online Networking The most e ective way to increase the pro le of your business is to take a Once you have signed up to attend the conference, join our LinkedIn group Company Pro le which will be available for the rst time online, as well as in the to network with your peers ahead of the conference. Find out who else conference documentation pack. will be going, connect with potential partners and set up meetings around the On-line event. A company pro le on the website is the most e ective way to promote your In addition you can engage in lively discussion and debate on the issues and brand and will give you immediate exposure to the entire bio-partnering challenges facing you today. community. The earlier you take a Company Pro le, the more exposure you will Search on LinkedIn for “The European BioBusiness Networking receive. Community” and link up with your peers as soon as you register! Documentation Pack In addition, a company pro le will give you a full page in the conference documentation pack and is a superb way to increase your exposure – use it to promote your business or detail your current plans. Increase Your Exposure At BioBusiness Network: Past Sponsors Include: The Leading Platform To Meet Your Business Development Objectives Boehringer Ingelheim • Apex Healthcare Consulting • If your goal is the present your organisation as a ‘partner of choice’, BioBusiness Network has been TVM Capital • Evaluate Pharma • VenTech • Capital Royalty designed to help you. Our event partners are ensured branding on our emails, brochures and LP • BTG • Wyeth • Taylor Wessing • Roche • Caprotech letters as well as throughout the conference itself. If you want to raise your pro le and get your Bioanalytics • Solvay Pharmaceuticals • UKTI • Czech Invest • message across to this year’s attendees, there are limited opportunities available for you to join the Lovells • Avercia • Novartis • Fulcrum Pharma • Novozymes • conference programme – by speaking on the agenda or joining a panel discussion. Index Ventures • Astellas Pharma For more details, contact Noj Mather at noj.mather@wbr.co.uk or call +44 (0)20 7368 9555. +44 (0) 207 368 9465 biobusiness@wbr.co.uk www.biobusinessnetwork.com 6133 AW.indd 4 28/05/2010 16:45
  4. 4. 29th – 30th September 2010, Intercontinental Hotel, Geneva MAIN CONFERENCE DAY ONE 29th September 2010 08.00 Registration and Co ee 12.00 – 17.00 One-to-One Partnering Meetings 08.40 Chairman’s Welcome One-to-One partnering meetings will run alongside the conference sessions. 08.50 10 Minute Master Class – Networking In A Nutshell Choose which conference sessions you would like to attend and build your Christopher Barrat, Director, Greystone Partnership personalised meeting agenda around your availability accordingly. You all come to BioBusiness Network to do just that – to network. But are you doing this as e ectively as you can? In this ten minute session, you will learn cutting-edge techniques to improve how you network and truly make the most out of your two days at BioBusiness Network 2010. 12.30 The Perfect Pitch: Biotech Investment Challenge In this innovative session, 6 Biotechs all focused on different therapeutic areas, will be given 09.00 Case-Study: Roche-Galapagos COPD Alliance – €400 Million the opportunity to present their “perfect pitch” to our audience of potential partners and Risk Sharing In Target Discovery To Product investors as well as to our panel of experts. Each Biotech will give a 10 minute company Louk Pechtold, Director Business Development, Roche presentation highlighting their current projects. Then our panellists, consisting of big Onno van de Stolpe. CEO, Galapagos Pharma, VCs and Investment Banks will give their feedback on the strengths of the pitches just heard- highlighting the portions of the presentations that piqued their interest. This will • Unique target discovery platform of Galapagos and the basis of the alliance not only give the presenting companies the platform to attract new partners, but will also • How Alliance covers both small molecules and antibody targets give the presenting companies, and audience alike, insight into what sparks the interest of • An overview of how Galapagos runs programmes in small molecules through to clinic potential partners and investors. This session is a must attend for Pharma, Biotechs, and the • Risk based alliance: success based milestones and royalties for Galapagos, option to license for Roche investment community. The panellists will then have a chance to confer and choose “the • A prime example of how biotech–pharma deals are changing from contract research and in-licensing to perfect pitch” which will be presented a BioBusiness Network Award risk sharing in combination with opt-in Contact Michaela Menezes on michaela.menezes@wbr.co.uk 09.30 Panel Discussion: Big Pharma Outlook To 2015 – Key Strategies to nd out more and join this exciting challenge. To Achieve Growth • Biotech #1 presentation (Oncology) Denise Goode, Executive Transaction Director – Strategic Planning and • Biotech #2 presentation (CNS & Psychiatry) Business Development, AstraZeneca • Biotech #3 presentation (Cardiovascular) Gary Buell, Head of Search and Evaluation, Early Stage Licensing, Merck • Biotech #4 presentation (Diabetes/Metabolic) Serono • Biotech #5 presentation (Infectious Disease) • Biotech #6 presentation (Auto-Immune (HIV)) Lubor Gaal, Head of Europe, Global Search, Strategic Transactions Group, Bristol Myers Squibb 13.30 Networking Lunch Marianne De Backer, Director Technology Licensing, Johnson & Johnson 14.30 Mastering The Art Of A Winning Pitch: Achieve A • Assessing the M&A landscape: how is the pharma world changing? • Analysing Big Pharma’s current business model and the mergers, acquisitions and divestments that have Competitive Edge And Secure Funding shaped the industry Christopher Barrat, Director, Greystone Partnership • What are the blockbuster drugs for the next five years? • What are pharma companies looking for from your pitch? • Is business development a major contributor to future growth in a tough market? • What constitutes a perfect pitch – from content to delivery? • Opportunities and prospects in 2011 • Delivering a first class pitch – dos and don’ts • Improving your communication style to align with Big Pharma 10.00 Speed Networking – Pre-Partnering Meeting Warm-Up! • Positioning your product heads and shoulders above the competition Introducing the fastest and most e ective way to meet the delegate audience! In just thirty minutes you will have the opportunity to meet and exchange business cards with everyone in the room! 15.00 Early Partnering Case Study: GSK / Astex – Building A Unique Strategic Drug Discovery Alliance 10.30 Morning Co ee Jeremy Carmichael, Head of Business Development, Astex and 11.00 Living Science, Transforming Lives leading representative, GSK Dr. Christoph Huels - Vice President Early Stage Licensing, Merck Serono • Indentifying the drivers that led to the early-stage deal • An overview of Merck Serono company activities • An overview of the GSK model and the basis of the GSK / Astex collaboration • Assessing the company’s approach to innovation and collaboration models • Outlining the alternatives to an option-based deal • Key interests for collaboration with external partners • Key steps to progressing the partnership within predefined parameters 11.30 Case Study: Elan Drug Technologies-Acorda Therapeutics 15.30 Afternoon Tea Ampyra Licensing And Development Partnership – The 16.00 Case Study: An Allosteric Odyssey: Partnering The Concept, The Technology, The Launch, The Potential MGluRs Blockbuster Vincent Mutel, PhD, CEO and Co-Founder, Addex Noeleen Kenny, VP Commercial Management and Dr Sarah Carty, Director, Pharmaceuticals Business Development, Elan Drug Technologies • Historical overview of the industry’s work on mGluRs • Early work in 1990’s in Elan on molecule • An overview of the Addex contribution • Acorda’s involvement - history of alliances between Elan and Acorda from 1997 to present • Exploring the Addex partnerships • The challenge of 4-AP and the formulation and process approach taken by Elan Drug Technologies • Other partnerships on mGluRs • The MXDAS™ technology, the clinical programme undertaken by Acorda and the launch in 2010 of • Drug-candidates targeting mGluRs in development Ampyra™ (dalfampridine) • Attributes of a successful business partnership and lessons learned 16.30 Improving Corporate Social Responsibility Via Public- Private Partnerships In Neglected Diseases 12.00 Biotech CEO Panel: Key Trends And The Biotech Vision For 2011 Prof. Patrick Nef, CBO, Medicines for Malaria Ventures (MMV) – Securing Deals And Progressing Projects • What socially responsible licensing means Francois Curtin, • How to ensure the dissemination of safe, efficacious and affordable treatments for CEO, Geneuro developing countries Alux Wu, • The product-development public-private partnership model for a global health impact CEO, Crown Biosciences • The MMV partnering and funding strategies to defeat malaria: 10 years of success/impact Roland Kozlowski, 17.00 Round-Table Discussions CEO, Lectus Therapeutics Rainer Lichtenberger, 18.00 Drinks Reception CEO, CEVEC Pharmaceuticals 19.00 Networking Dinner • Will biotechs continue to play the role of chief innovator? (For details visit, www.biobusinessnetwork.com) • The increase in virtualisation: what do biotechs need to do to stay ahead? • How can biotech companies maintain a competitive edge in a challenging market? • Exploring alternative funding strategies to secure deals and progress projects +44 (0) 207 368 9465 biobusiness@wbr.co.uk www.biobusinessnetwork.com 6133 AW.indd 5 28/05/2010 16:45
  5. 5. 29th – 30th September 2010, Intercontinental Hotel, Geneva MAIN CONFERENCE DAY TWO 30th September 2010 08.15 Registration and Co ee 12.00 Panel Discussion: Exploring New And Alternative 08.50 Chairman’s welcome Models To Enhance Future R&D Collaboration Darren Ji, CEO, PharmaLegacy Laboratories 09.00 NEW FOR 2010! Early-Stage Workshop Jay Maden, Vice President, Business Development to New for 2010 and by popular demand, we bring you an exclusive, interactive forum for biotechs and big Biopharmaceuticals, Reliance Life Sciences 12.00 pharma involved in early-stage deals to come together and develop strategies to overcome top challenges. Benedikt Timmerman, CEO, GENTICEL The workshop will consist of interactive roundtable discussions as well as practical hands-on insight giving Kees Been, CEO, Envivo Pharmaceuticals you the opportunity to address key topics, including: • Which R&D developments and innovative new treatments will expand the pharma • Identifying strategies for survival and growth biotech market? • Funding opportunities for early stage biotechs: what are the options of financial backing and the • Key ways to cost-effectively and innovatively increase R&D capabilities and secure new advantages and disadvantages of these opportunities? R&D partnerships • Exploring suitable partners to drive scientific ideas from discovery research to clinical stage testing and market approval • Who is responsible for driving R&D collaboration and how are such partnerships structured? • Breaking down recent early-stage deals: what works and what doesn’t • Evaluating the latest technologies to drive R&D innovation and ensure long term industry • An analysis of high-profile early stage deal case studies sustainment • Improving strategic planning to balance risk with reward • Solving the pre-clinical translation problem To ensure participants have maximum opportunity for interaction and beneficial discussion, places are strictly limited. To register your place, contact the conference organisers at biobusiness@wbr.co.uk. 12.30 – 17.00 One-to-One Partnering Meetings. 09.00 Case Study: The Acquisition Of Novexel By AstraZeneca One-to-One partnering meetings will run alongside the conference sessions. Olivier Litzka, Partner, Edmond de Rothschild Investment Partners Choose which conference sessions you would like to attend and build your Iain Buchanan, CEO, Novexel personalised meeting agenda around your availability accordingly. Karen Gallant, Business Development Director, Infection in Strategic Partnering and Business Development, AstraZeneca 12.30 Pharma/Biotech M&A – Exclusive Preview Of The New • Context of the anti-infective market and the need for novel approaches • Company profile in anti-infectives: Novexel and AstraZeneca HBM Report • Assessing the strategic rationale for M&A and the structure of the transaction Chandra Leo, Partner, HBM Capital • The outcome: success factors and lessons learned The new M&A environment has been created by recent changes in the pharmaceutical landscape, public markets and private financings. In this session, HBM Partners analyses the 09.30 Panel Discussion - BioPharma Focus: What Can Big latest trends in pharma/biotech trade sales from around the world. Pharma Learn From The Biotech World? • How are the number and volume of M&A deals evolving? Roland Kozlowski, CEO, Lectus Therapeutics • Who are the most active buyers and what are their deal terms? Paula Zeilon, CEO, Alligator BioScience • And which companies are today’s hottest acquisition targets? Kees Lucas, Managing Director, Life Science Consultancy 12.45 Investment Challenge – Awards and Feedback Kim Koh Bill, Vice-President, Corporate Development, Debiopharm • Balancing the innovation and entrepreneurship of biotechs with the structure and 13.00 Networking Lunch organisation of big pharma 14.00 Modern Day Pharma Collaborations – The Open • Advantages of being big (financial strength and organisation resilience) versus the inhibitors (bureaucracy and inflexibility) Innovation Approach • Can you be big and small at once? Peter Luke, Senior Director, Strategic Alliances, P zer • Bridging the communication gap between pharma and biotech companies 14.30 Biotech Focus: Top Tips To Raise Capital In A Changing • How can deal-making be improved if pharma learn a lesson or two from their biotech partners? World 10.00 Case Study: Merck & Co. Entering The German Chemical Jason Slingsby, CEO, ProtA n Biotechnologie Space - An Overview Of The Deal With Elexopharm • How to avoid a funding crisis: what you need to know Dr Manfred Horst, Director Scienti c Liaison, France and Germany, • Evaluating your investment needs based on size and stage of development Merck & Co • Exploring the options: from venture capitalists to academic grants and angel investors • Adapting your proposition based on market conditions and project needs 10.30 Panel Discussion: The Emergence And Growth Of Corporate VCs – Understanding The Issues And 15.00 Harnessing Academia-Industry Partnerships To Drive Evaluating The Players Drug Discovery Roel Bulthuis, Head – Merck Serono Ventures Laura MacDonald, Head of Licensing, LURIS, University of Leiden Graziano Seghezzi, Partner, So nnova Partners • Successful collaboration: tried and tested models “’versus”” new innovative partnerships • Tried and tested models : new technologies taken forward - rare diseases and rheumatoid arthritis Alan Warrander, Director, Warrander Consulting • Innovative models for collaboration: risk sharing and expertise pooling across public • The increasing prominence of big pharma in funding early-stage drug discovery and sector and industry development: strategic objectives and compensation structures • Avoiding the risks associated with long-term partnerships and licensing deals 15.30 Afternoon Tea • Outlining the challenges and opportunities for biotechs: from funding to investment policies • Does the growth in CVCs inhibit future partnering prospects or will they rise to the challenge? 16.00 Evaluating New Projects And Opportunities From The • Assessing the pros and cons from the perspective of biotechs Perspective Of A Biotech Manfred Groeppel, Business Development Director, 4SC 11.00 Morning Co ee • Valuation tools: an overview of useful gears 11.30 Panel Discussion: Is the Partnering Paradigm Alive • The aspects and relevance of input data: success rates, duration, DCF, peak sales etc. And Well? • Examples and what can we learn from the rNPV of a project? Magnus Bjorsne, Business Development Director, AstraZeneca 16.30 Case Study: Antisense + SiRNA Therapeutics: A Jeremy Carmichael, Head of Business Development, Astex Turbulent Past, A Bright Future Nigel Sheail, Global Head of Licensing, Roche Elias Papatheodorou, CEO, Novosom Katherine Cohen, Global Head of Corporate & Business Development, • A review of the developments of the last 5 years Intercell • Major roadblocks: what challenges have been overcome and what can we still expect? Gary Deeb, VP of Global Licensing & Business Development, • Current programmes in the clinic Glenmark Pharmaceuticals • Future directions and strategic goals Carlos De Sousa, Vice-President Corporate Licensing, Nycomed 17.00 Chairman’s Summary and End of Conference • Is the age of doing a deal and retaining partnering over in the pursuit for fast bucks? • Is partnering the sole customer or is there the game of building new companies? • What does the future look like for partnering and how do you need to adapt? +44 (0) 207 368 9465 biobusiness@wbr.co.uk www.biobusinessnetwork.com 6133 AW.indd 6 28/05/2010 16:46
  6. 6. 29th – 30th September 2010, Intercontinental Hotel, Geneva Just Some Of The Companies That Have Attended Biobusiness Network Include: BT Pharma Elan LifeCycle Pharma A/S Rhein Biotech Cambridge Theranostics Ltd Elchrom MC2 Biotek Sano -Aventis Caprion Pharmaceuticals Inc Eli Lilly Merck KGaA Santaris Pharma CDC Innovation Enzon Pharmaceuticals Merck Serono Scottish Biomedical Celgene Equateq MerLion Scynexis Cellzome Inc ERYtech Pharma Merrion BioPharma Ltd.. Selcia Ltd. Cerbios-Pharma SA Evotec Micromet Seventure Partners Cerimon Pharmaceuticals F. Ho mann-La Roche Ltd MMI Group Solvay Pharmaceuticals Gmbh CEVEC Pharmaceuticals GmbH Forest Laboratories Inc Modern Biosciences Staatz Chemical Diversity Labs, Inc. Galantos Pharma Neovacs SA Symphogen AS Chimaerabio GlaxoSmithKline Neumann International Synosia Therapeutics Chroma Therapeutics Ltd Glycotope GmbH Neurim Pharmaceuticals Syntaxin Ltd CLARA - Cancéropôle Lyon Auvergne HBM BioVentures Ltd Notox B.V Takeda Global R&D Centre Rhône-Alpes Hybrigenics Novartis Horsham Research Centre TechnoPhage SA CMS Cameron McKanna Hyglos GmbH Novo Nordisk AS Teva Pharmaceutical Industries Ltd Compugen IDIS Novozymes A/S Theratechnologies inc. Coulter Partners Immunehealth Paion Deutschland GmbH Transgene SA Cubist Pharmaceuticals Index Ventures Peakdale Molecular Ltd Transperfect Life Sciences Practice Cyprotex Discovery Intercell AG P zer Limited TVM Capital Czech Invest Jado Technologies Pharmalink AB Ventech Dafra Pharma International Janssen Cilag Ltd PolyTherics Ltd VIB Debiopharm Johnson & Johnson Probiodrug AG Vifor Pharma Ltd. Dyax Corp Kempen & Co Procter & Gamble Xplico A/S Eisai Europe Limited Kenta Biotech Ltd Proteros Hear What Your Peers Have To Say About BioBusiness Network 2010: “ We thoroughly enjoyed the eye-opening seminars. BioBusiness allows a more intimate, honest and constructive exchange of opinions than other conferences” Rami Suzuki, Senior Manger, Oncology, Corporate Business Development, Eisai “ I attend many conferences in my role at GSK, but I certainly found this event to be of very high quality and extremely useful ” Kate Burt, Director, Commercial Alliances and Transactions, Worldwide Business Development, GlaxoSmithKline “ This was a meeting of the right size and focus to put together industry representatives with common goals and to allow su cient time and space to have meaningful discussions. It was also well-coordinated ” Kay Wagoner, CEO, Icagen “ A very successful event for me, both the informal and formal networking is outstanding ” Christine Lemke, VP Business Development, Medigene “ The size and exclusivity of the audience at BioBusiness make it an extremely productive Bio-partnering event ” Margaret Beer, Scienti c Liason, Merck Take Home The BioBusiness Group Savings! Network CD Rom Bring your teams and take advantage of our tremendous savings: At this year’s event we will be recording the presentations, discussions and debates on CD Rom so that you don’t miss out on any of the action while 2 delegates – save 15% 3 delegates – save 20% +4 delegates – save 25% you take part in your one-to-one partnering meetings. Capture all the detail of the sessions and learn at your own pace when you get back to the o ce. Group discounts do not apply to sponsoring or exhibiting companies. Please note that no two discounts can For details, see the back page be combined. To qualify for the discount, the entire group must be booked and paid for at the same time. +44 (0) 207 368 9465 biobusiness@wbr.co.uk www.biobusinessnetwork.com 6133 AW.indd 7 28/05/2010 16:46
  7. 7. 29th – 30th September 2010, Intercontinental Hotel, Geneva About Our Sponsors: Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. In the United States and Canada, EMD Serono operates through separately incorporated a liates. Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta- 1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets. With an annual R&D expenditure of over € 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and in ammatory diseases. For more information, please visit www.merckserono.com or www.merck.de Nycomed is a privately owned global pharmaceutical company with a di erentiated portfolio focused on branded medicines in gastroenterology, respiratory and in ammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is built to be open for partnerships as in-licensing is a cornerstone of the company’s growth strategy. Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed will further strengthen its position in key Asian markets. Headquartered in Zurich, Switzerland, the company generated in 2009 total sales of €3.2 billion and an adjusted EBITDA of €1.075 billion. Elan Drug Technologies, the world’s leading drug delivery business delivers clinically meaningful bene ts to patients, by using their extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies, to develop new and innovative products. From bioavailability enhancement technologies for poorly water soluble compounds, to customised oral drug technologies, they o er our clients unrivalled drug delivery expertise with a suite of commercially launched, proprietary, technology-driven solutions. With 40 years experience in the drug delivery business, they have successfully brought 36 drugs to market for clients in over 100 markets worldwide. They also have extensive product development, scale-up and manufacturing capabilities in the US and EU with over 500,000 sq ft of FDA/EMEA licensed facilities under roof and the capacity to manufacture over 2.5 billion solid oral dosages annually. Products enabled by their technologies are used by millions of patients each day. More information is available at www.elandrugtechnologies.com Teva Pharmaceuticals one of the world’s top 20 pharmaceutical companies and is the leader in generic pharmaceuticals. Teva also has proprietary (or innovative) pharmaceuticals on the market and has a strong pipeline of innovative projects in clinical development. Teva Innovative Ventures is seeking to increase further this Innovative pipeline by partnering or licensing pre-clinical programs via our exible partnership models. We are looking for therapies for CNS disorders (with emphasis on multiple sclerosis), autoimmune diseases, in ammatory diseases and oncology. Our key criteria are that the opportunities are at a development stage between lead molecule and rst-in-man dosing, have strong IP, meet a clear unmet medical need and that they can show differentiation from current clinical care. We source novel programs from University groups, spin-out or start- up companies, and from smaller Biotech. We aim to rapidly develop our partners’ innovative therapies through our global development organisation, and make them available for patients. Teva currently operates in over 60 countries and has around 35,000 employees worldwide. Merck & Co., Inc., is an innovative, global health care leader that is committed to improving health and well-being around the world. Merck discovers, develops, manufactures, and markets vaccines, medicines, and consumer and animal health products designed to help save and improve lives. The recent merger of Merck and Schering-Plough greatly expands our combined company’s product o erings in a range of areas, including heart and respiratory health, infectious diseases, and women’s health. We continue to focus our research on conditions that a ect millions of people around the world — diseases such as Alzheimer’s, diabetes, and cancer — while expanding our strengths in areas like vaccines and biologics. Merck invests heavily in research and development. Our strategy for growth is based on breakthrough research — both internal and external through partnerships — and demonstrating the value of our medicines to patients, payers, and providers. At today’s Merck, we’re applying our global reach, nancial strength and scienti c excellence to do more of what we’re passionate about: improving health and improving lives. Merck is strongly committed to partnership success. For all the original research we conduct, we know that the next great discovery in medicine may well come from outside of our laboratories. This is why the formation of strategic partnerships is a central part of our business and research strategy. For further information, please visit our Web site at http://www.merck.com/licensing/ Supported by: BioAlps, the fastest growing life science cluster in the world. BioAlps, the Western Switzerland life science cluster, is rated the third European centre for research into biotechnology and medical technologies after Cambridge and Oxford in the United Kingdom. It covers more than 700 biotech and medtech companies, 500 research laboratories, some 20 world-famous research institutions, universities and university hospitals, as well as numerous bodies supporting innovation including science parks, incubators of start-up companies and venture capital funds. Above all, it is a centre of excellence which attracts many famous scientists. This stems as much from its dynamic nature as from its resources in research and development and its dense industrial fabric, which o er so many opportunities. www.bioalps.org Media Partners: O cial PR partner +44 (0) 207 368 9465 biobusiness@wbr.co.uk www.biobusinessnetwork.com 6133 AW.indd 8 28/05/2010 16:46
  8. 8. BioBusiness Network 2010 29th – 30th September 2010, Intercontinental Hotel, Geneva www.biobusinessnetwork.com Booking Ref: 2. Registration Options (please tick) Biotech & Big Pharma 1. Delegate Details Bookings received by Bookings received by Final Price Surname (Mr/Mrs/Ms).................................................................................................................................. Friday 25th June Friday 30th July Name ...................................................................................................................................................................... Conference Only £1579 £1679 £1779 Job Title ................................................................................................................................................................. Conference + £1978 £2078 £2178 Company Profile Department........................................................................................................................................................ CD Rom £299 Head of Department .................................................................................................................................... Others Registration Contact ..................................................................................................................................... Bookings received by Bookings received by Company.............................................................................................................................................................. Final Price Friday 25th June Friday 30th July Address.................................................................................................................................................................. Conference Only £2199 £2299 £2399 .................................................................................................................................................................................... Conference + £2598 £2698 £2798 .................................................................................................................................................................................... Company Profile City ........................................................................................................................................................................... CD Rom £299 Post Code............................................................................................................................................................. *All prices are subject to 7.6% Swiss VAT Country ................................................................................................................................................................. Fax back on +44 (0)20 7368 9401 Email (required) ................................................................................................................................................ Alternatively please mail to: BioBusiness Network 2010, WBR Ltd, Anchor House, 15-19 Britten Street, Tel.............................................................................................................................................................................. London, SW3 3QL, United Kingdom. Fax ............................................................................................................................................................................ Or email biobusiness@wbr.co.uk Tel: +44 (0)20 7368 9465 Company VAT No. ........................................................................................................................................... Web: www.biobusinessnetwork.com 3. YES! I wish to register for BioBusiness Network 2010 Your information will be held and used by Worldwide Business Research Limited (“WBR”) to register you for this conference and/or we may contact you by email, phone or post with information about other conferences, products and services, which our associated companies or we provide. We may also from time to time share your information with other parties in the European Economic Area who may wish to contact you by phone or post, in relation to special o ers, products and services related to your role within your company. If you would prefer not to receive such information from us or such third parties, please fax us, including a copy of this page, on UK free phone fax number 0800 652 5943 or +44 20 7368 9401 PAYMENT DETAILS: Payment should be received by WBR Ltd within 7 days of the invoice date or by expiry of given discount date whichever is earliest. If payment is not received by the o ered discount date the higher price will apply. Any booking made in the 14 days prior to the conference must be paid by credit card. Payment of invoices other than by means of credit cards or purchase order (UK PLC and Government bodies only) will be subject to a £49 (plus VAT) processing fee Please charge my AMEX/VISA/MASTERCARD (please delete as applicable) Card no ....................................................................................................................................................................................................... Security Code. ................................................ Expiry Date. .................................................. Cardholder’s Name ............................................................................................................................................................. Cardholder’s Signature .............................................................................................................................. or I will be sending a bank transfer to Worldwide Business Research Ltd’s bank: HSBC, 79 Piccadilly, London W1J 8EU. GBP payments to be made to: A/C No: 21243578, Sort Code: 40-05-26, IBAN: GB09MIDL40052621243578, BIC: MIDLGB2107L. Please fax con rmation of the bank transfer to Credit Control on +44 (0)20 7368 9401, quoting delegate’s name and booking code 11230.004 as your reference on both fax and bank transfer or I enclose a cheque made payable to WBR Ltd WBR Ltd Cancellation, Postponement and Substitution Policy: You may substitute delegates at any time by providing reasonable advance notice to WBR. For any cancellations received in writing not less than twenty two (22) days prior to the conference, you will receive a 90% credit to be used at another WBR Ltd conference which must occur within one year from the date of issuance of such credit. An administration fee of 10% of the contract fee will be retained by WBR Ltd for all permitted cancellations. No credit will be issued for any cancellations occurring within twenty one (21) days (inclusive) of the conference. In the event that WBR Ltd cancels an event for any reason, you will receive a credit for 100% of the contract fee paid. You may use this credit for another WBR Ltd event to be mutually agreed with WBR Ltd, which must occur within one year from the date of cancellation. In the event that WBR Ltd postpones an event for any reason and the delegate is unable or unwilling to attend in on the rescheduled date, you will receive a credit for 100% of the contract fee paid. You may use this credit for another WBR Ltd event to be mutually agreed with WBR Ltd, which must occur within one year from the date of postponement. Except as specified above, no credits will be issued for cancellations. There are no refunds given under any circumstances. WBR Ltd is not responsible for any loss or damage as a result of a substitution, alteration or cancellation/postponement of an event. WBR Ltd shall assume no liability whatsoever in the event this conference is cancelled, rescheduled or postponed due to a fortuitous event, Act of God, unforeseen occurrence or any other event that renders performance of this conference impracticable, illegal or impossible. For purposes of this clause, a fortuitous event shall include, but not be limited to: war, fire, labor strike, extreme weather or other emergency. Please note that while speakers and topics were confirmed at the time of publishing, circumstances beyond the control of the organizers may necessitate substitutions, alterations or cancellations of the speakers and/or topics. As such, WBR Ltd reserves the right to alter or modify the advertised speakers and/or topics if necessary without any liability to you whatsoever. Any substitutions or alterations will be updated on our web page as soon as possible. 6133 AW.indd 1 28/05/2010 16:46

×